Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical ...

TORONTO--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough ...

Researchers have developed a mindfulness therapy tailored specifically to appeal to teenagers to help them cope with increasing levels of depression and mental health problems.